Launch Campaign Hub — 6 Slots

America was told the cigarette was dying. On October 21, Philip Morris reported 3.2 billion ZYN pouches shipped in the United States in three months, 20-pouch cans coming to optimize the price premium, and, in the words of its chief executive Jacek Olczak, “the exceptional results of our combustible business.” Altria sells on!. Same companies, same customer, with or without the smoke.

Why?

Because the customer was never the smoke. It was the nicotine. A 2025 meta-analysis found a 4-milligram pouch delivers about 92 percent of a cigarette’s nicotine. The FDA authorized ZYN in January 2025 for carrying substantially fewer of the constituents that kill smokers, and said in the same breath that this does not make it safe.

The bill is public: more than 600 billion dollars in 2018, the last year the CDC priced it. The states take 21.7 billion this fiscal year in tobacco taxes and settlement money and spend 3.4 percent of it on helping anyone quit; the industry outspends that nearly twelve to one on marketing. In 2006 a federal court found the cigarette makers had for decades conspired to deny the health effects of smoking, and ordered them to print what they had hidden.

Now the man at his desk at two in the afternoon. Nicotine works: forty-one placebo-controlled studies found it sharpens attention and memory, modestly, in people not in withdrawal. Take it away for seventeen hours and, in thirty daily smokers on a sustained-attention test, reaction time slowed, errors rose and responses scattered; a review of 120 studies lists difficulty concentrating as a withdrawal symptom that peaks in the first week. The focus he buys is, in part, the focus the last one took back. Dependence, sold as productivity. Four in ten pouch ads running in the US right now sell that switch.

So, two pouches with no nicotine in either, every milligram printed. One for the morning: 75 milligrams of caffeine with 100 of theanine, 100 of theacrine for the long tail, citicoline at 225. One for the rest of the day with no caffeine at all: paraxanthine at 200, citicoline at 250.

We will not promise to get anyone off nicotine. We will not call this safer than a product the FDA spent years reviewing. We will say what is in it, to the milligram, and ask a man why focus has to come with a hook in it.

Every figure is on file, read Oct 21: PMI’s SEC-filed Q3 2026 release (3.2 billion, 20-pouch cans, price premium, the Olczak quote) · Altria’s on! release · the 2025 meta-analysis in Drug and Alcohol Dependence Reports (91.73%) · FDA’s Jan 16 2025 authorization · CDC ($600B in 2018) · Campaign for Tobacco-Free Kids FY2026 ($21.7B, 3.4%, 12 to 1) · U.S. v. Philip Morris, D.C. Cir. 2017, in the court’s words · Heishman 2010, Psychopharmacology (41 studies, d 0.16–0.44) · Harrison 2009, Exp Clin Psychopharmacol (n=30, 17 h) · Hughes 2007, Nicotine Tob Res (120 studies) · the Oct 21 census (41% of live US pouch ads on the switch). Table with links: dossier §8c. The only join is “in part”: Heishman measures the gain outside withdrawal, Harrison and Hughes the loss inside it; no single study measures both in one person.

Does the approved calendar follow the record? On six points, yes: 14 days inside the 17-day rule (arcs ≤17 days $0.279 per email vs $0.175 for 18+); an occasion for launch day (occasion arcs $0.423 at the ask vs $0.219 for bare launches); the last chance is run (Sleepy Cocoa's close out-earned its own launch day); no holiday interrupt in the window; no repeated qualifier into launch week; product-free values before a reveal. On three it does not take what the record offers: no telegraph (NMN's launch-tomorrow named the offer and printed $0.455, the slot's ceiling; median $0.165 over 13 sends); the third build is the reveal, which was coffee's trough ($0.069), not a value that earns on its own; and the two value types that carried the nattokinase and black-seed run-ups are absent: the discovery blog (natto #3 What Dr. Sumi Found and What They Buried for 40 Years, $0.140; black seed's El-Dakhakhny reveal, $0.135) and the mechanism blog (natto #4 The Microclot Scandal, $0.164, the best value send of that arc). Below is the same window with those three put back.

What the record says this costs, and buys

• Four builds instead of three. Across 18 arcs, 1–2 builds earn $0.310 per email and 3+ earn $0.179, and inside occasion arcs the ask after 3+ builds ($0.419) is no better than after two ($0.425): the run-up's job is done by send two. Both calendars already sit in the 3+ bucket; this one adds a fourth. It pays only if 03 and 04 earn on their own, as natto's did ($0.140, $0.164) and NMN's did ($0.255, $0.319), and not as coffee's did ($0.093, $0.076, $0.069).
• The telegraph. Thirteen launch-tomorrow sends, median $0.165. The one that named the offer is the ceiling ($0.455). Natto's 1-day join converted 2.6× its telegraph; coffee's 1-day join did not ($0.087 → $0.137). The telegraph is worth running only if it names the offer.
• Launch day leaves the dark Monday. The occasion is kept by the telegraph (the clock change is Sunday night, the telegraph goes out Monday morning) and launch day is Tuesday. If the Monday launch matters more than the telegraph, drop 05 and this is the approved calendar with one extra build.
• Still absent from both calendars: a VIP or early-access mechanic, which printed the best per-recipient numbers of the year (presale apology to ~3k VIPs $1.923; BSO's ~310-person segments $3.94 and $1.50; coffee's 1,095 buyers split $1.076), and an offer before launch day, which every launch before coffee ran and coffee did not. Neither is a value type; both are a slot in extras.
• Fatigue is untested, not disproven. Opens are flat across build positions 1–8 (~41%), but every arc on record opens with builds, so the record cannot price a shorter run-up either way.

Decision. Not adopted. The approved calendar and its six tasks stand until Juan says otherwise. Adopting this means two new slot tasks (03, 05), re-dating EM-284 to Oct 30, EM-285 to Nov 3 and EM-286 to Nov 5, a second blog build in the copy lane before Oct 28, and the paraxanthine/citicoline primaries read before 03 is written. Figures from the launch-history page (Klaviyo campaign values, pulled Sep 2 and Oct 20 2026) and the 18-arc RPR analysis; none re-pulled for this block.

Job of the arc: three product-free builds (Oct 23, 26, 29 reveal) into a launch (Nov 2) and a two-step close (Nov 4, 6). Occasion: the first dark Monday after the clocks go back.

• Every number from a primary source, fetched and read, before it reaches copy.
• Generic ingredient names only. Cognizin, TeaCrine and enfinity are competitor language.
• SKU-002 is caffeine-free, never stimulant-free.
• No cessation framing: never 'quit', 'replace your nicotine', 'wean'. Customers' own words may be quoted with a permalink.
• 'Dietary supplement' and Supplement Facts language are gated until the regulatory lane answers the DSHEA ingestion question.
• Prices print as targets until Juan locks them; the formula is the concept page until a label exists.
• Never attack caffeine, sweeteners, glycerin or 'synthetic' as a category: the product carries all of them.
• Alt text five words or fewer; GlockApps preflight on subject and wrapper before scheduling.

Dates, subjects and audience come from the approved content calendar and it wins any disagreement. Canon (canon.json) is the formula's source of truth; when copy and canon disagree, canon wins. check_flow.py runs before every deploy.